address1,address2,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,forwardPE,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,epsTrailingTwelveMonths,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,prevName,nameChangeDate,cryptoTradeable,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,longName,marketState,regularMarketChangePercent,regularMarketPrice,shortName,hasPrePostMarketData,firstTradeDateMilliseconds,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,trailingPegRatio
Kungsbron 1,"Level 3, Elevator G",Stockholm,11122,Sweden,46 8 13 33 10,https://cincluspharma.com,Drug Manufacturers - Specialty & Generic,drug-manufacturers-specialty-generic,Drug Manufacturers - Specialty & Generic,Healthcare,healthcare,Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.",19,"[{'maxAge': 1, 'name': 'Dr. Lennart  Hansson Ph.D.', 'age': 68, 'title': 'Co-founder & Chairman of the Board', 'yearBorn': 1956, 'fiscalYear': 2024, 'totalPay': 495000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christer  Ahlberg', 'age': 53, 'title': 'CEO & President', 'yearBorn': 1971, 'fiscalYear': 2024, 'totalPay': 5663000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Unge', 'age': 73, 'title': 'Co-founder & Director', 'yearBorn': 1951, 'fiscalYear': 2024, 'totalPay': 1941000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Maria  Engstrom', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jesper  Wiklund', 'age': 55, 'title': 'Director of Corporate & Business Development', 'yearBorn': 1969, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kajsa  Larsson', 'age': 58, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,2,16.82,16.9,16.2,16.96,16.82,16.9,16.2,16.96,0.0,47584,47584,140764,45747,45747,16.3,16.52,767873728,9.31,35.3,167.65802,14.9452,17.12506,0.0,0.0,SEK,False,215504096,-1.8987342,0.0,31783914,46537800,0.33143002,0.34855998,46656400,10.994,1.5008186,1735603200,1767139200,1743379200,-164808000,-3.54,47.053,-1.197,-0.5,0.12969577,EQUITY,16.5,75.0,50.0,61.66667,60.0,none,3,523899008,11.257,-180046000,383000,12.044,12.708,4580000,0.075,0.109,-0.36716998,-0.83217,4580000,-120328624,-184664992,1.0,0.0,-39.33974,SEK,CINPHA.ST,en-US,US,Equity,Delayed Quote,True,HIGH,-3.54,-6.89,-2.3947752,1.5548,0.1040334,-0.6250591,-0.036499675,15,0,Cinclus Pharma Holding AB,2025-07-16,False,[],1752679795,STO,finmb_645865099,Europe/Stockholm,CEST,7200000,se_market,False,Cinclus Pharma Holding AB (publ),PREPRE,-1.9024954,16.5,Cinclus Pharma Holding AB,False,1718866800000,-0.3199997,16.2 - 16.96,Stockholm,140764,7.1899996,0.7722878,9.31 - 35.3,-18.8,-0.5325779,-50.0,
